Stay updated on Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.

Latest updates to the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check63 days agoChange DetectedThe webpage has undergone significant updates, including the addition of a new study on the efficacy of rifaximin combined with N-acetylcysteine for treating Irritable Bowel Syndrome with Diarrhea (IBS-D), and the revision number has been updated to v2.15.0. Notably, the previous detailed description of IBS and its treatment has been removed.SummaryDifference24%
Stay in the know with updates to Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.